VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain Oct 3, 2018
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder Sep 13, 2018
VistaGen Therapeutics and Baylor College of Medicine Collaborate on First-Step Study to Test VistaGen’s AV-101 for Potential Anti-Suicidal Effects in Veterans Aug 13, 2018
VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights Jun 26, 2018
VistaGen Therapeutics Issued Two Key U.S. Patents for Treatment of Depression with AV-101 Jun 13, 2018
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent for Use of Stem Cells to Treat Cancer and Autoimmune Disorders Jun 11, 2018
VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries with Stem Cell-Derived Chondrocytes and Cartilage May 23, 2018
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101 May 2, 2018
VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101 Apr 10, 2018
